TCT 2024｜详细日程速览！26项LBCT/LBCS临床研究即将重磅发布！

10月27日至10月30日，第36届年度经导管心血管治疗年会（TCT2024）会议将在美国华盛顿隆重开幕。TCT大会聚焦心血管介入领域最新研究和前沿科技，旨在通过介入治疗改善心脏病和血管疾病患者生存率和生活质量。

本年度TCT会议主题为“从干预到预防：实现持久结果的综合管理”，探索如何将预防措施与介入治疗相结合，以更全面地对抗和减轻心血管疾病。

在为期4天的会议期间设置了6场LBCT/LBCS，共26项冠脉疾病、结构性心脏病等心血管最新临床研究，届时呈现这些成果的顶尖科学家和来自全球的顶尖临床医生进行互动讨论，碰撞学术火花。

严道医声特此汇总整理，以供速览！

Late-Breaking Clinical Science：Session l, in Collaboration with the European Heart journal

北京时间：18:00-19:30 pm

1.Comparison of Noncompliant Balloon With Drug-Coating Balloon Angioplasties for Side Branch After Provisional Stenting for Patients With True Coronary BIFurcation Lesions: The Prospective, Multicenter, Randomized DCB-BIF Trial

真性冠状动脉分叉病变患者临时支架置入术后侧支非顺应性球囊与药物涂层球囊血管成形术的比较：前瞻性、多中心、随机DCB-BIF试验

2.Early Administration of Heparin at First Medical Contact Versus in the Cathlab for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention (HELP-PCI): A Multicenter, Randomized Trial

对于接受直接经皮冠状动脉介入治疗的STEMI患者在第一次医疗接触时早期在导管室中给予肝素治疗：多中心随机HELP-PCI试验

3.Comparison of Puncture Success Rate Between Distal Radial Access and Transradial Access in Patients With ST-Elevation Myocardial Infarction

ST段抬高型心肌梗死患者远端桡动脉入路与经桡动脉入路穿刺成功率的比较

4.1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent From the INFINITY-SWEDEHEART Randomized Clinical Trial

INFINITY-SWEDEHEART随机试验中的复杂病变患者亚组中，比较当代DES与DynamX Bioadaptor的一年和6-12个月临床结果

5.Artificial-Intelligence Enabled Quantitative CT Assessment of Atherosclerosis and Major Adverse Events: The Multi-Center International CONFIRM2 Registry

人工智能对动脉粥样硬化和主要不良事件的定量CT评估：多中心国际CONFIRM2注册研究

Late-Breaking Clinical Trials: Session ll, in Collaboration with The Lancet

北京时间：15:00-16:30 pm

1.ECLIPSE: A Large-scale, Randomized Trial of Orbital Atherectomy vs. Conventional Balloon Angioplasty in Severely Calcified Coronary Arteries Prior to DES Implantation

ECLIPSE：DES 植入前严重钙化冠状动脉的轨道斑块旋切术与常规球囊血管成形术的大规模随机试验

2.CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine Versus Placebo and Spironolactone Versus Placebo in Patients With Myocardial Infarction: The Results of the Colchicine Factorial

CLEAR SYNERGY（OASIS 9） 试验：秋水仙碱与安慰剂和螺内酯与安慰剂在心肌梗死患者中的 2x2 析因随机对照试验：秋水仙碱分析结果

3.Large-bore Mechanical Thrombectomy vs Catheter-directed Thrombolysis for Treatment of Intermediate-Risk Pulmonary Embolism: Primary Outcomes From the PEERLESS Randomized Controlled Trial

大口径机械血栓切除术与经导管溶栓治疗中危肺栓塞：PEERLESS 随机对照试验的主要终点

4.Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

SIRONA 随机对照试验：西罗莫司涂层球囊与紫杉醇涂层球囊在股腘动脉血管成形术中的头对头比较

Late-Breaking Clinical Trials: Session ll, in Collaboration with the journal of the American Medical Association

北京时间：15:00-16:30 pm

1.TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

TRISCEND II 试验：严重三尖瓣反流患者经导管瓣膜置换术与最佳药物治疗的结果

2.One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

ACURATE neo2与批准的TAVR设备在所有风险重度AS患者中的一年结果

3.Quantitative Flow Ratio or Fractional Flow Reserve for Guiding Coronary Revascularization

用于指导冠状动脉血运重建的定量流速比（QFR）或血流储备分数（FFR）

4.Artificial Intelligence-Based Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH): Multicenter, Randomized Controlled Non-Inferiority Trial

基于AI的全自动定量冠状动脉造影（QCA）与光学相干断层扫描（OCT）引导冠状动脉支架植入术（FLASH）：多中心、随机对照非劣效性试验

Late-Breaking Clinical Science: Session III, in Collaboration with Circulation

北京时间：15:00-16:30 pm

1.The TARGET-IV Trial: International Multicenter Randomized Assessment of the Firehawk® Rapamycin Eluting Coronary Stent System

TARGET-IV试验：Firehawk®雷帕霉素洗脱冠状动脉支架系统的国际多中心随机评估

2.Prospective, Multicenter, Open-Label, Randomized Controlled Trial of 3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial

植入可生物降解聚合物Firehawk西罗莫司洗脱冠脉支架后，3个月与12个月双重抗血小板治疗的前瞻性、多中心、开放标签、随机对照试验：TARGETDAPT试验的主要结果

3.Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: The CLEAR IE Multicenter Registry

右侧感染性心内膜炎经皮机械抽吸的结果：CLEARIE多中心登记处

4.CLASP IID Randomized Trial and Registry: Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation

CLASP IID随机试验和注册：经导管缘对缘修复治疗退行性二尖瓣反流的两年结果

5.Transcatheter Repair Versus Surgery in Atrial Mitral Regurgitation: Results From the MATTERHORN Trial

经导管修复与手术治疗房性二尖瓣反流：MATTERHORN试验的结果

Late-Breaking Clinical Trials: Session l, in Collaboration with the New England journal of Medicine

北京时间：15:00-16:00 pm

1.Transcatheter Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: Results of the EARLY TAVR Trial

经导管主动脉瓣置换术治疗无症状重度主动脉瓣狭窄：EARLY TAVR试验结果

2.Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Left Ventricular Myocardial Fibrosis

无症状重度主动脉瓣狭窄合并左心室心肌纤维化患者的早期干预

3.Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: The TAVR UNLOAD Trial

收缩性心力衰竭和中度主动脉瓣狭窄患者的经导管主动脉瓣置换术：TAVR UNLOAD 试验

Late-Breaking Clinical Science: Session ll, in Collaboration with the journal of the American College of Cardiology

北京时间：15:00-16:00 pm

1.Colchicine in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: A Double-Blind Randomized Controlled Trial

秋水仙碱治疗接受经导管主动脉瓣置换术的主动脉瓣狭窄患者：一项双盲随机对照试验

2.Comparison of Strategies for Vascular Access Closure After Transcatheter Aortic Valve Implantation: The ACCESS-TAVI Randomized Trial

经导管主动脉瓣植入术后血管通路关闭策略的比较：ACCESS-TAVI 随机试验

3.Cerebral Embolic Protection in the US Cohort of the PROTECTED TAVR Trial

PROTECTED TAVR试验：美国队列中的脑栓塞保护装置的结果

4. Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

女性患者经导管主动脉瓣置换与外科主动脉瓣置换术：RHEIA 和 PARTNER 3 试验的汇总分析

5.The ALIGN-AR Trial: Two-Year Outcomes of Transcatheter Aortic Valve Replacement With JenaValve TrilogyTM in High Surgical Risk Patients With Moderate-to-Severe or Severe Native Aortic Regurgitation

ALIGN-AR 试验：JenaValve TrilogyTM 经导管主动脉瓣置换术在中度至重度或重度自体主动脉瓣反流高手术风险患者中的两年结果

· END ·

版权及免责声明：严道医声网旨在搭建学术传播及媒体发声平台，文内信息版权属于持有人，我们只提供传递信息之用。如有侵权，请联系我们删除。